A fierce debate has erupted in the American healthcare landscape, pitting academic researchers against powerful provider trade groups over the financial legacy of the No Surprises Act (NSA). At the center of this controversy is a staggering $22 billion estimate of "unnecessary spending" attributed to the Independent Dispute Resolution (IDR) process—a figure that provider groups are now aggressively challenging as a product of flawed methodology.
The conflict highlights the ongoing struggle to balance consumer protection with fair market compensation, revealing deep-seated distrust between insurers and the medical professionals tasked with delivering care.
The Core Dispute: Defining "Excessive" Costs
The controversy stems from a report published Wednesday by researchers at Georgetown University. The study posits that the IDR mechanism, designed to protect patients from surprise out-of-network medical bills, has resulted in over $22 billion in additional spending over the last four years. Of that total, roughly $16 billion is attributed specifically to arbitration awards that exceeded the median in-network rates.
For proponents of the research, the data serves as a wake-up call. The NSA was passed in 2020 with the noble intent of removing patients from the middle of billing disputes between insurers and providers. However, critics argue that the implementation of the IDR—the "baseball-style" arbitration process—has inadvertently incentivized providers to bypass contract negotiations in favor of seeking higher payouts through federal arbitration.
A Chronology of the IDR Escalation
To understand the current volatility, one must look at the timeline of the No Surprises Act’s implementation:
- January 2022: The No Surprises Act takes effect, prohibiting providers from balance-billing patients for out-of-network services and establishing the IDR process to resolve payment disputes.
- 2022–2023: Early reports suggest the IDR process is significantly more utilized than anticipated. An initial estimate suggests the process generated approximately $5 billion in costs during its first two years.
- 2024–2025: The volume of claims explodes. Arbitrators find themselves overwhelmed by a backlog of cases, while researchers begin to note a trend of providers securing "generous" awards.
- February 2025: The Congressional Research Service (CRS) releases a report analyzing the Qualifying Payment Amount (QPA), finding that in some regions, the metric fluctuates significantly compared to other market benchmarks.
- August 2025: A federal court strikes down the existing methodology for calculating the QPA, agreeing with provider groups that the formula was overly influenced by insurer-controlled data.
- September 2025: Georgetown University researchers release their report claiming $22 billion in total excess costs, triggering a swift and sharp rebuttal from major medical associations.
The Foundation of the Argument: The QPA Controversy
The crux of the current disagreement is the "Qualifying Payment Amount" (QPA). Under the NSA, the QPA is intended to serve as the median in-network rate for a specific service in a specific geographic area. It acts as the primary benchmark for arbiters when deciding which party’s offer—the insurer’s or the provider’s—is more reasonable.
Provider Groups Push Back
In a joint statement released Thursday, the American Society of Anesthesiologists (ASA), the American College of Emergency Physicians (ACEP), and the American College of Radiology (ACR) denounced the Georgetown study. These groups represent specialties that were frequently subject to surprise billing prior to the 2022 legislation.
Their argument is straightforward: The QPA is not a neutral, accurate reflection of the market. They contend that insurers calculate the QPA themselves and have a vested interest in keeping that number artificially low. "The report’s cost claim is built on a deeply flawed premise: that the insurer-calculated QPA is accurate and represents an appropriate in-network payment rate," the groups stated. They argue that if the benchmark itself is skewed downward, any calculation of "excess" costs based on that benchmark is fundamentally invalid.
The Academic Defense
Jack Hoadley, a professor at Georgetown’s Center on Health Insurance Reforms and a co-author of the study, maintains that the researchers accounted for these provider grievances.
To test the sensitivity of their findings, Hoadley and his colleagues re-ran their analysis using 150% and 200% of the QPA as the benchmark. Even when adjusting for higher thresholds, the researchers still concluded that the costs were in the billions. Hoadley remains firm, stating, "There are features in the data that may cause that to be an underestimate, and features in the data that may cause that to be an overestimate. We still think that [the $22 billion figure] is a good estimate."
Supporting Data and Market Realities
The debate over the QPA is not merely academic; it has real-world consequences for contract negotiations. When providers believe the QPA is artificially suppressed, they have little incentive to sign long-term, in-network contracts with insurance companies. Instead, they opt for the "arbitration gamble," hoping that an independent arbiter will award them a rate closer to their billed charges than the insurer’s offer.
Data from the Congressional Research Service (CRS) adds nuance to the discussion. Their February report found that the QPA is not uniformly low. In six states, the QPA was actually lower than other measures of median in-network rates, but in eight states, it was higher. This suggests that the "QPA problem" may be highly regional, making a one-size-fits-all critique of the metric difficult to sustain.
Furthermore, recent federal court rulings have empowered providers. The decision earlier this month to vacate the methodology for calculating the QPA represents a major victory for medical groups. By forcing insurers to recalculate these figures, the court has effectively opened the door for higher arbitration awards, potentially fueling the very "cost inflation" that researchers like Hoadley are highlighting.
Implications for the Healthcare Ecosystem
The implications of this standoff are profound, affecting everything from private equity involvement in medicine to the stability of the insurance market.
1. The Role of Private Equity
Regulators and health policy experts are increasingly concerned that private equity-backed medical groups are weaponizing the IDR process. By utilizing sophisticated legal and data-analysis teams, these large groups are able to win arbitration cases at a higher frequency, potentially inflating their profit margins at the expense of overall system costs.
2. The Erosion of In-Network Contracting
If the IDR process remains more lucrative than negotiated in-network rates, the fundamental goal of the No Surprises Act—which was to encourage fair, market-based contracting—may be undermined. As arbitration continues to serve as a profitable alternative, the incentive for providers to remain in-network diminishes, which could lead to narrower provider networks for patients, ironically contradicting the spirit of the legislation.
3. A Need for Regulatory Reform
The consensus among policy experts is that the QPA, in its current form, is nearing the end of its useful life. Whether it is replaced by a different benchmark, a more transparent calculation method, or a complete overhaul of the IDR process, the "war of attrition" between providers and insurers has made the status quo untenable.
"Clearly it’s an opportunity to rethink the QPA and decide if there’s a better measure," Hoadley noted. "I’m certainly comfortable with the idea that we should be looking into alternatives. But at the moment, it’s what we have."
Conclusion
As the dust settles on the recent $22 billion cost estimate, the divide between the healthcare industry’s various stakeholders remains wider than ever. While the No Surprises Act succeeded in its primary goal—protecting patients from unexpected financial ruin—it has created a secondary crisis of systemic cost and administrative complexity.
The path forward requires a level of transparency that currently does not exist. Until insurers can provide a QPA that is accepted as legitimate by providers, and until providers can demonstrate that their arbitration claims are based on market value rather than profit-seeking, the cycle of litigation and escalating costs is likely to continue. For now, the $22 billion figure serves as a sobering reminder that while the "surprise" has been removed from the patient’s bill, it has been transferred directly into the complex and often contentious machinery of the American healthcare administrative state.
